204
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Dyspnea During Night-Time and at Early Morning in Patients with Stable COPD is Associated with Supine Tidal Expiratory Flow Limitation

, , ORCID Icon, , &
Pages 2549-2558 | Published online: 16 Oct 2020

References

  • PartridgeMR, KarlssonN, SmallIR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. COPD requires round-the-clock symptom control. Curr Med Respir Opin. 2009;25(8):2043–2048. doi:10.1185/03007990903103006
  • KesslerR, PartridgeMR, MiravitllesM, et al. Symptom variability in COPD. Eur Respir J. 2011;37(2):264–272. doi:10.1183/09031936.0005111021115606
  • Lopez-CamposJL, CaleroC, Quintana-GallegoE. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231–238. doi:10.2147/COPD.S4286623687444
  • AgustiA, HednerJ, MarinJM, BarbèF, CazzolaM, RennardS. Night time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20(121):183–194.21881146
  • LangeP, MarottJL, VestboJ, NordestgaardBG. Prevalence of night-time dyspnea in COPD and its implication for prognosis. Eur Respir J. 2014;43(6):1590–1598. doi:10.1183/09031936.0019671324488571
  • MillerMR, CrapoR, HankinsonJ, et al. General considerations for lung function testing. Eur Respir J. 2005;26(1):1533–1611. doi:10.1183/09031936.05.00034505
  • Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary (report-2017). Available from: http://www.goldcopd.org.
  • KoulourisNG, ValtaP, LavoieA, et al. A simple method to detect expiratory flow limitation during spontaneous breathing. Eur Respir J. 1995;8(2):306–313. doi:10.1183/09031936.95.080203067758567
  • DellacàRL, SantusP, AlivertiA, et al. Detection of expiratory flow limitation using the forced oscillation technique. Eur Respir J. 2004;23(2):232–240. doi:10.1183/09031936.04.0004680414979497
  • NewtonMF, O’DonnellDE, ForkertI. Response of lung volume to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002;121(4):1042–1050. doi:10.1378/chest.121.4.104211948031
  • QuanjerPH, TammelingGJ, CotesJE, PedersenOF, PeslinR, YernaultJC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5–40. doi:10.1183/09041950.005s1693
  • MiravitllesM, WorthH, Soler CatalunaJJ, et al. Observational study to characterize 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15(1):122–135. doi:10.1186/s12931-014-0122-125331383
  • TantucciC. Expiratory flow limitation: definition, mechanisms, methods, and significance. Pulm Med. 2013;2013:749860. doi:10.1155/2013/74986023606962
  • MiravitllesM, WorthH, Soler CatalunaJJ, et al. The relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an observational study (ASSESS). Chronic Obstruct Pulm Dis. 2016;13(5):561–568.
  • StephensonJJ, CaiQ, MocarskiM, TanH, DoshiJA, SullivanSD. Impact and factors associated with night-time and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577–586. doi:10.2147/COPD.S7615725844033
  • NunesDM, MotaRM, de Pontes NetoOL, PereiraED, de BruinVM, de BruinPF. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009;187(3):159–163. doi:10.1007/s00408-009-9147-519399553
  • OmachiTA, BlancPD, ClamanDM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476–483. doi:10.1016/j.sleep.2011.12.00722429651
  • EltayaraL, GhezzoH, Milic-EmiliJ. Orthopnea and tidal expiratory flow limitation in patients with stable COPD. Chest. 2001;119(1):99–104.11157590
  • KimV, HanMK, VanceGB, et al. The chronic bronchitis phenotype of COPD. An analysis of the COPD gene study. Chest. 2011;140(3):626–633.21474571
  • VestboJ, PrescottE, LangeP. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Crit Care Med. 1998;153(5):1530–1535. doi:10.1164/ajrccm.153.5.8630597
  • PatelIS, VlahosI, WilkinsonTM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Crit Care Med. 2004;170(4):400–407. doi:10.1164/rccm.200305-648OC
  • CalverleyPMA, KoulourisNG. Flow limitation and dynamic hyperinflation key concepts in modern respiratory physiology. Eur Respir J. 2006;25(1):186–199. doi:10.1183/09031936.04.00113204
  • GagnonP, GuenetteJA, LangerD, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:187–201.24600216
  • O’DonnellDE, WebbKA, NederJA. Lung hyperinflation in COPD: applying physiology to clinical practice. Chronic Obstruct Pulm Dis. 2015;1(1):4–16.